Current Report Filing (8-k)
December 11 2014 - 4:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 5, 2014
PROTEO, INC.
(Exact name of registrant as specified in its
charter)
Nevada |
|
000-30728 |
|
88-0292249 |
(State of other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification
No.) |
|
|
|
|
|
2102 Business Center Drive, Irvine, California 92612 |
(Address of Principal Executive Offices) |
|
|
|
|
|
Registrant’s telephone number, including area code: (949) 253-4155 |
|
Not Applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 5, 2014, Proteo,
Inc. (the “Company”) announced that Dr. Juergen Paal was appointed as the Chief Operating Officer of Proteo Biotech
AG, the Company’s wholly owned subsidiary, effective December 1, 2014. He will be responsible for Proteo's clinical development
program, product launch preparation, business development and partnering initiatives.
Dr. Paal, who is 43 years
old, has been a member of the scientific advisory board of Proteo Biotech AG since March 2006 and has more than 13 years’
experience in research and development, corporate strategic management and business development. From October 2012 to December
2014, Dr. Paal served as director business development therapeutic apheresis at Fresenius Medical Care. From May 2010 to September
2012, Dr. Paal was heading the strategic coordination office of Fresenius Medical Care EMEALA. From November 2007 to April 2010
Dr. Paal served as manager international strategic development at Fresenius Medical Care. Before he worked for 5 years at Altana
Pharma AG in Research and Development and Strategy Development.
A copy of the press release
announcing Dr. Paal’s appointment is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein
by this reference.
Item 9.01 Financial
Statements and Exhibits.
|
(d) Exhibits. |
|
|
|
|
Exhibit No. |
Description |
|
|
|
|
99.1 |
Press Release dated December 5, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROTEO, INC. |
|
|
Date: December
11, 2014 |
By: |
/s/ BIRGE BARGMANN |
|
|
Birge Bargmann Chief Executive Officer |
EXHIBIT INDEX
Exhibit |
|
Number |
Description |
|
|
99.1 |
Press Release dated December 5, 2014 |
Exhibit 99.1
Proteo Biotech
AG Expands Management Board
2014-12-05
IRVINE,
CA & KIEL, Germany - Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the
company strengthens its Management Board. The Supervisory Board of Proteo Biotech AG has appointed Dr. Juergen Paal as a new member
of the company’s Management Board, effective from Dec 1st, 2014. In this leadership role as Proteo Biotech AG's new Chief
Operating Officer, he will be responsible for Proteo's clinical development program, product launch preparation, business development
and partnering initiatives.
This
appointment follows Dr. Paal's involvement with Proteo Biotech AG since 2006 when he joined the scientific advisory board. Dr.
Paal has worked in two major international health care companies where he has acquired more than 13 years of experience in research
and development, corporate strategic management and business development. Dr. Paal joins from Fresenius Medical Care, where he
held a director's position with responsibility for business development in therapeutic apheresis.
"We
welcome Juergen to the Management Board. We have profited greatly from Juergen's contributions in his former advisory role for
Proteo, and together with his international working experience in leading positions in the health care industry, his appointment
to the Management Board represents an important cornerstone in the preparation for the commercialization of Elafin" said
Birge Bargmann, Chief Executive Officer, and Oliver Wiedow, Chairman of the Supervisory Board..
Dr.
Paal commented: "It is an exciting moment to join Proteo Biotech AG at this advanced stage of the clinical development of
the company's drug candidate Elafin after the drug has shown promising results in phase I and phase II clinical trials. The major
focus is now on the pivotal clinical trial with Elafin in its lead indication, and the exploration of partnering opportunities
for the marketing and distribution of Elafin to exploit the full commercial potentials of this promising product."
About
Proteo
Proteo, Inc. is
a Nevada corporation and has one wholly owned subsidiary, Proteo Biotech AG, a German corporation. The Company is a clinical stage
drug development company focusing on the development of anti-inflammatory treatments for rare diseases with significant unmet
needs (www.proteo.de).
Forward-Looking
Statements
Certain
statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act
of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All
statements, other than statements of fact included in this release, including, without limitation, statements regarding potential
future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be
no assurance that such statements will prove to be accurate and actual results and future events could differ materially from
those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically
significant plan(s) outlined above. The company cautions that these forward looking statements and risks and uncertainties involved
are further qualified by other factors including, but not limited to those set forth in the company’s Form 10-K filing and
other filings with the United States Securities and Exchange Commission. The company undertakes no obligation to publicly update
or revise any statements in this release, whether as a result of new information, future events or otherwise.
Proteo (GM) (USOTC:PTEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Proteo (GM) (USOTC:PTEO)
Historical Stock Chart
From Jul 2023 to Jul 2024